



Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

MERCK KGaA EXPANDS AND EXTENDS THEIR LICENSE OF METACORE FROM GENEGO

St. Joseph, Michigan, September 26th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Merck KGaA, Germany, (in the U.S.: EMD) has expanded their MetaCore license to allow all Merck KGaA employees to access MetaCore and the license is in perpetuity. Merck KGaA values the completeness of content coverage in MetaCore from signaling ligands to core metabolic changes, its intuitive interface and the system's applicability in many therapeutic areas and biomarkers.

“We see MetaCore as a further step into systems biology, a novel discipline which holds much promise for pharmaceutical research,” said Dr Friedrich Rippmann, Director of Bio- and Chemoinformatics.

“We are very pleased to expand our relationship with Merck KGaA. Our experience with them as a customer is very positive, with excellent, constructive, feedback and open exchange of development ideas” said Julie Bryant, Vice President of Business Development at GeneGo. “Now, more groups at Merck KGaA will be able to use MetaCore in both early discovery and new compound safety testing.”

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based [pathway analysis](#), cheminformatics & [bioinformatics software](#) for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, [proteomics](#), metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.0™, assists pharmaceutical scientists in the areas of target selection and validation, [data mining](#) in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.

MetaCore™, MetaBase™ and MetaDrug™ are trademarks of GeneGo, Inc.